Sign in
Taking peopleNo phase

Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis

Key facts

Who runs it
Assistance Publique Hopitaux De Marseille
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
250 people, planned
Started
2 Feb 2026
Expected to end
24 May 2029
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • blood sampling
  • blood sampling after 3-4 months
Record updated
28 October 2026

Who can take part

Age
6 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Experimental group:
  • Male or female, 6 to 65 years of age
  • Anorexia nervosa diagnosed according to DSM-5 criteria
  • Presence of undernutrition according to HAS 2019 criteria
  • Patient having received information about the study and having signed an informed consent form
  • Beneficiary or beneficiary of a social security scheme; Control group:
  • Minor patients :; Male or female strictly under 18 years of age; Patients undergoing scheduled non-inflammatory surgery (orthopedic, ENT, etc.); Patients who have been informed about the study and have signed an informed consent form; Patients who are beneficiaries or entitled beneficiaries of a social security scheme
  • Patients without anorexia with livers cytolysis :; Male or female between 18 and 65 years of age; With hepatic cytolysis determined by an ALT value at least equal to twice the normal value; Patient having received information about the study and having signed an informed consent form; Patient who is a beneficiary or eligible beneficiary of a social security scheme
  • samples Etablissement Français de don de sang: no specific criteria

Who cannot take part

  • Psychiatric disorder preventing patient consent to study
  • Patient in a period of exclusion from another research protocol at the time consent is signed
  • Opposition of patient and parents or legal guardians
  • Person unable to understand the French language
  • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Anorexia nervosa (AN) is a psychiatric disorder belonging to the eating disorders (EDs). It is internationally recognized as a priority for improving health care. Among the markers of severity of undernutrition is hepatic cytolysis. Around 30-50% of patients with AN present with hepatic cytolysis, of variable intensity, and usually associated with severe undernutrition. In a previous study, we demonstrated the presence of autoantibodies against HIF1alpha (Hypoxic inducible Factor 1 alpha) in 22% of cases in a sample of patients with AN. HIF1alpha (HIF1a) is a major transcription factor involved in the regulation of satiety and hunger. These autoantibodies were positive in 80% of AN patients with hepatic cytolysis. Taken together, these data led us to hypothesize an anti-HIF1a autoimmune mechanism in AN, potentially involved in the patients' hepatic cytolysis.

Read full original descriptionShow less

This pioneering study, demonstrating the existence of anti-HIF1a autoantibodies, was carried out on a population of 18 patients with AN. To extend investigator's hypothesis, these results need to be confirmed on a larger number of patients, thus increasing the number of patients with AN and hepatic cytolysis. To determine the relevance of these autoantibodies in AN, "healthy" subjects and patients without AN but with hepatic cytolysis should be tested in parallel. Finally, the in vitro pathogenic potential of autoantibodies can be confirmed on a larger scale and studied in greater detail.

The main aim of our study is to evaluate the association between the presence of anti-HIF1a autoantibodies (AAHIF) and that of hepatic cytolysis in patients with anorexia nervosa and undernutrition.

This study is a prospective, cross-sectional, descriptive, multicenter, 2-arm study.

250 patients will be included. Experimental group (n=100)

* Patients with anorexia nervosa and undernutrition with hepatic cytolysis (CH) (n=70) * Patients with anorexia nervosa and undernutrition without hepatic cytolysis (n=30) Comparator control groups (n=150) * Control patients under 18 years of age, treated at the CHU de la Timone for scheduled non-inflammatory surgery (orthopedic, ENT, etc.) (n=50): Minor patients * Patients (children and adults) with hepatic cytolysis without anorexia nervosa (n=50): Patients without AN with CH * Samples from French blood donation establishment: control group consisting of biological blood samples from healthy individuals from the Etablissement Français du Sang (n=50)

The 4 groups in the trial

  • Patient with anorexia nervosa and anti-HIF1a autoantibody positivityTreatment being tested

    When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. In the event of AAHIF positivity, a second sample will be taken between 12 and 16 weeks later to verify the persistence of autoantibodies: Visit 2. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).

    Treatment: blood sampling and blood sampling after 3-4 months

  • Patient with anorexia nervosa and no anti-HIF1a autoantibody positivityTreatment being tested

    When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).

    Treatment: blood sampling

  • Patient without anorexia nervosa and anti-HIF1a autoantibody positivityExisting treatment, for comparison

    When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. In the event of AAHIF positivity, a second sample will be taken between 12 and 16 weeks later to verify the persistence of autoantibodies: Visit 2. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).

    Treatment: blood sampling and blood sampling after 3-4 months

  • Patient without anorexia nervosa and no anti-HIF1a autoantibody positivityExisting treatment, for comparison

    When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).

    Treatment: blood sampling

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Fit questions
Built from NCT06869590, who can take part
Record updated
28 October 2026